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This supplement is based on the proceedings of
the integrated symposium ‘Lipopeptides: the
class of 2006’, which took place at the 16th
European Congress of Clinical Microbiology and
Infectious Diseases (ECCMID) in Nice during
April 2006.
Gram-positive bacteria such as Staphylococcus
aureus are a major cause of serious infections. The
increasing prevalence of antibiotic resistance
among these pathogens presents today’s clini-
cians with several challenges. Chief among these
is the requirement to treat infections caused by a
diverse range of drug-resistant Gram-positive
pathogens with a diminishing number of effective
treatment options.
The opening article of this supplement focuses
on three clinically important examples of
drug-resistant Gram-positive pathogens: vanco-
mycin-resistant enterococci (VRE), multidrug-
resistant coagulase-negative staphylococci, and
methicillin-resistant S. aureus (MRSA). The spread
of hospital-acquired MRSA (HA-MRSA) has been
well-documented; however, MRSA is no longer
confined to the healthcare setting, and frequent
reports of community-acquired MRSA (CA-
MRSA) have emerged over the past decade. To
date, HA-MRSA and CA-MRSA have been
viewed as separate entities with different anti-
biotic susceptibilities and genetic backgrounds.
The opening article discusses the increasingly
blurred relationship between HA-MRSA and CA-
MRSA and highlights the potential implications
of uncontrolled CA-MRSA infection in residential
nursing homes.
The global response to the spread of MRSA and
other antibiotic-resistant pathogens has involved a
number of strategies, including enhanced surveil-
lance and control efforts by several national and
international agencies. These agencies—such as
the US Centers for Disease Control and Prevention
(CDC) and the European Centre for Disease
Prevention and Control (ECDC)—have imple-
mented a number of initiatives to prevent and
control the spread of antibiotic resistance and
healthcare-associated infection. While such initia-
tives are undoubtedly important, there is still an
urgent need for novel therapeutic agents to treat
serious infections caused by drug-resistant Gram-
positive pathogens. Among the most recently
approved agents is daptomycin, the first of a
new class of antibiotics, the cyclic lipopeptides.
The antimicrobial characteristics of daptomycin
are described in the second article of the supple-
ment. The concept of ‘antimicrobial wild-type
susceptibility distributions’ is introduced and
new data quantifying the in-vitro activity of
daptomycin against a wide range of Gram-
positive bacteria are presented. In-vitro experi-
ments have shown that daptomycin possesses
rapid, concentration-dependent bactericidal activ-
ity against Gram-positive organisms. The bacteri-
cidal activity of daptomycin is only slightly
reduced by an increase in inoculum density and
is maintained in the stationary phase of bacterial
growth. The second article also discusses the
protein-binding characteristics of daptomycin and
examines current evidence for its potential
efficacy in the treatment of biofilm infections.
Bringing a US perspective to the issue of
antibiotic resistance in S. aureus, the third article
summarises MRSA surveillance data from the
National Nosocomial Infections Surveillance
(NNIS) system and other US surveillance pro-
grammes. Also reviewed is evidence demonstra-
ting that infection with MRSA is associated with
increased morbidity and mortality compared
with infections caused by methicillin-susceptible
S. aureus. The increasing prevalence of MRSA in
the USA has contributed to a reliance on the
glycopeptide vancomycin. Importantly, infections
caused by MRSA with reduced susceptibility to
vancomycin have recently become apparent. This
phenomenon is one of several factors that have
prompted the use of daptomycin in the USA.
Also described in the third article are the
clinical studies that have established the efficacy
of daptomycin for the treatment of complicated
skin and soft tissue infections (cSSTIs), and, more
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recently, S. aureus bacteraemia and infective
endocarditis. Daptomycin is currently licensed
in Europe and the USA for the treatment of cSSTIs
in adults. In the USA, daptomycin has also been
approved for the treatment of S. aureus bacterae-
mia and right-sided infective endocarditis. A
European Union application for these additional
indications has recently been submitted.
In the final article, the deleterious impact of
antibiotic resistance on the number of options
available for the treatment of serious Gram-
positive infections is highlighted. Treatment
options for staphylococcal and enterococcal
infections have been particularly compromised.
The rising prevalence of HA-MRSA and CA-
MRSA has been followed by an increase in the
number of infections caused by VRE. The final
article also reviews the changing molecular
epidemiology of infections caused by MRSA
and VRE, and predicts an increase in difficult-
to-treat Gram-positive infections over the com-
ing years. Such predictions confirm the need for
new treatment options. The properties of dap-
tomycin suggest that this agent could be a
useful option for the treatment of serious Gram-
positive infections.
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